Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
Petar Seferović, John J.V. McMurray(Western Infirmary), Frank Ruschitzka(University Hospital of Zurich), Johann Bauersachs(Medizinische Hochschule Hannover), Walter J. Paulus(Amsterdam UMC Location VUmc), Gerasimos Filippatos(National and Kapodistrian University of Athens), Henrik Wiggers(Aarhus University Hospital), Theresa A. McDonagh, Rudolf A. de Boer(University Medical Center Groningen), Arno W. Hoes(University Medical Center Utrecht), Ivan Milinković(University of Belgrade), Jillian Riley(Lung Institute), Ekaterini Lambrinou, Jennifer Logue(University of Glasgow), Jelena P. Seferović(University of Belgrade), Mitja Lainščak, Mamas A. Mamas(Royal Stoke University Hospital), Dimitrios Farmakis, Marija Polovina(University of Belgrade), Giuseppe Rosano(Vita-Salute San Raffaele University), Dirk J. van Veldhuisen(University of Groningen), Francesco Cosentino(University of Zurich), Michael J. Theodorakis(National and Kapodistrian University of Athens), Wolfram Doehner, Alexandre Mebazaa, Massimo Piepoli, Aldo P. Maggioni, Carsten Tschöpe(Franklin University), Stefan D. Anker, John Lekakis(British Heart Foundation), Yu. M. Lopatin(Volgograd State Medical University), Michel Komajda(Institute of Cardiology), Mark C. Petrie(Copenhagen University Hospital)
Cited by 714
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k